Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prospective multicenter observational study of atezolizumab combination therapy in patients with unresectable, advanced and recurrent non-small cell lung cancer or extensive disease small cell lung cancer

Next Previous
X
Search
Trial Profile

Prospective multicenter observational study of atezolizumab combination therapy in patients with unresectable, advanced and recurrent non-small cell lung cancer or extensive disease small cell lung cancer

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 15 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atezolizumab (Primary) ; Antineoplastics
  • Indications Non-small cell lung cancer; Small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms J-TAIL-2
  • Sponsors Chugai Pharmaceutical

    • Most Recent Events

    • 04 Jun 2024 Results (data cut off (Feb 3, 2023), N=814) assessing the efficacy and safety of 3 atezo combination therapies for NSCLC in the clinical setting in Japan were presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
    • 04 Jun 2024 Results (n=403, data cutoff (Feb 3, 2023)) evaluating the efficacy and safety of atezo + CE in Japanese pts in the clinical setting were presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
    • 01 Apr 2024 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top